Corrigendum to "DPP-4 Inhibitor Dose Selection According to Manufacturer Specifications: A Contemporary Experience From UK General Practice" [Clinical Therapeutics 41 (8) (2019) 1622-1630]

Clin Ther. 2020 Apr;42(4):726-727. doi: 10.1016/j.clinthera.2020.02.001. Epub 2020 Feb 15.

Authors

Dionysis Spanopoulos¹, Michael Busse¹, Joanne Webb², Abigail Tebboth¹, Nicholas D Gollop³, Michael W Marcus¹

Affiliations

¹ Boehringer Ingelheim Ltd, Berkshire, United Kingdom.
² Eli Lilly and Company, Basingstoke, United Kingdom.
³ Boehringer Ingelheim Ltd, Berkshire, United Kingdom. Electronic address: nick.gollop@boehringer-ingelheim.com.

PMID: 32067743
DOI: 10.1016/j.clinthera.2020.02.001

No abstract available

Publication types

Published Erratum